50 COVID-19 positive patients in Department of Haematooncology, Faculty hospital Ostrava in 2020

Authors

  • Barbora Hájková Klinika hematoonkologie, Fakultní nemocnice Ostrava
  • Ondrej Šušol Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Jana Mihalyova Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Michal Kaščák Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Juraj Ďuraš Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Jana Zuchnicka Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Hana Plonkova Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Katarina Hradska Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Tereza Popkova Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Katerina Benkova Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Tomas Jelinek Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Zdenek Koristek Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Milan Navratil Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Jaromir Gumulec Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Ivo Demel Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • David Buffa Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Lukas Stejskal Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Ludmila Muronová Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Barbora Dluhosova Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Roman Hajek Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Hana Zelena Centrum klinických laboratoří, Zdravotní ústav se sídlem v Ostravě , Department of Virology, Institute of Public Health, Ostrava, Czech Republic
  • Lenka Szeligova Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava
  • Lucie Dudova Klinika hematoonkologie, Fakultní nemocnice Ostrava , Department of Hematooncology, University Hospital Ostrava

Keywords:

Coronavirus, COVID-19, hematooncology, multiple myeloma, immune suppression, immunoparesis

Abstract

Novel coronavirus (SARS-CoV-2) is a highly contagious disease with significant mortality rate. Among the most endangered are hematological patients. We evaluate course of the disease, link between comorbidities and COVID-19 severity and seroconversion ability in 50 positive patients of our clinic.

We performed 1600 diagnostic PCR nasopharyngeal swabs during a period of 8 months. We introduced a group of preventive measures so as to protect our patients and personnel. In 50 COVID positive patients, we closely evaluate the course of the disease, the impact of underlying risk factors and main hematological diagnoses. We also evaluate the ability of seroconversion in 15 COVID-19 positive patients.

Crucial in reducing the spread of disease have shown to be strict barrier measures, especially in patients undergoing autologous stem cell transplantation. We did not notice any disease outbreak, and only one positive case during the peritransplant period in our facility. The most common comorbidities were arterial hypertension or other cardiovascular disease, type 2 diabetes and renal impairment. Two-thirds of positive patients were on first line of treatment. Hypogammaglobulinemia did not prove as a risk factor of severe COVID course and we did not observe it to be an obstacle for seroconversion. 

Preventive measures are significant in reducing the spread of disease, especially in hematologic centers. In our single center experience we report mortality of 14%. Although we report a relatively small cohort and much remains yet to be clarified, our results can be even now translated to everyday use.

Downloads

Published

2021-12-01